A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy

Phase 3 CoMpass is SPA-agreed, fully enrolled (108 pts), sham-controlled with time-to-tumor-progression endpoint. Positive Phase 2 end-of-study data and mechanistically strong VDC with FDA Fast Track/Orphan support success odds above base rate. However, small trial size, sham control durability, and 15-month endpoint variability add risk. Topline not until 2H27, well past this market's window—resolution timing risk is significant.reasoning tilts moderately positive.:

Phase 3 RCT, masked, sham-controlled for bel-sar vs control in IL/small CM. Primary endpoint: time-to-tumor progression (65 weeks). Active not recruiting, enrollment complete. Standard pivotal design with adequate power expected; no design/operational red flags in fields.

Phase 2 data demonstrated an 80% tumor control rate in Phase 3-eligible patients, with the tumor growth rate dropping from 0.351 mm/yr pre-treatment to 0.011 mm/yr post-treatment (p<0.0001). The Phase 3 CoMpass trial enriches for patients with documented tumor growth prior to enrollment and compares bel-sar to a sham control, making a positive time-to-progression result highly probable.

Phase 3 sham-controlled trial of novel light-activated therapy for small choroidal melanoma. Prior Phase 2 data encouraging but small; risk of sham arm performing better than expected and masking challenges. Time-to-progression endpoint is objective but progression determination may be influenced. Typical Phase 3 oncology success ~40-50%, so intrinsic odds slightly below 50%.

Bel-sar (AU-011) showed strong Phase 2 signals in indeterminate lesions and small choroidal melanoma, with high rates of tumor shrinkage and low progression. The time-to-progression endpoint against sham control is well-suited to demonstrate benefit given expected progression in untreated arm. Phase 3 risk remains, but mechanism and prior data support a positive outcome.

Bel-sar targets indeterminate lesions/small melanoma with a novel mechanism. Phase 2 data showed strong efficacy in preventing progression. The primary endpoint (time to progression) is objective. Active status suggests operational stability. Historical success in this niche supports a positive outcome, though Phase 3 risks remain.

Phase 3 ocular melanoma trial with time-to-progression endpoint at 65 weeks. Bel-sar is a novel viral-like drug-device combo with promising Phase 2 data but limited long-term follow-up. Sham control in vision-threatening tumors creates ethical/operational execution risk and potential unmasking. Small tumor population and indeterminate lesion heterogeneity may dilute effect. 460 days to completion adds disclosure risk. Prior data supportive but not definitive; mechanism is innovative but unproven at scale.

Bel-sar Phase 3 with rigorous sham-controlled design in small choroidal melanoma/indeterminate lesions. Encouraging Phase 2 tumor control data and FDA Breakthrough Designation support optimism, but Phase 3 transition risk, novel viral-nanoparticle laser-activated mechanism, and small Phase 2 cohorts (n<50) create meaningful uncertainty. Sham control may progress slower than historical controls, making bar higher. Active not recruiting status suggests clean enrollment. Overall slightly below coin-flip given execution risks in rare ocular oncology.